生物制剂使用影响类风湿关节炎中炎症对主要不良心血管事件风险的作用
在10国观察性队列的4370例无心血管疾病类风湿关节炎患者中,随访26534患者年发生239例主要不良心血管事件(MACE)和362例缺血性心血管事件(iCVE)。DAS28-CRP与bDMARD使用对MACE存在显著交互作用(p=0.017),DAS28-CRP每增加1单位在bDMARD未使用者中与MACE风险相关(HR 1.21,95%CI 1.07-1.37),在使用者中无此关联(HR 0.69,95%CI 0.40-1.20);CRP交互作用亦显著(p=0.011)。
要点
- DAS28-CRP与bDMARD使用对MACE风险存在显著交互作用(p=0.017)。
- bDMARD未使用者中DAS28-CRP每增1单位MACE风险HR 1.21(95%CI 1.07-1.37),使用者中HR 0.69(95%CI 0.40-1.20)。
- bDMARD使用与DAS28-CRP或CRP对iCVE风险无显著交互作用(p=0.167和p=0.237)。
核心结论
- RA疾病活动度和炎症标志物与bDMARD未使用者的MACE风险相关,而与使用者无关,提示生物制剂可能对动脉壁有局部益处且独立于全身炎症效应。
研究设计与样本
- 10国观察性队列研究,纳入4370例无心血管疾病的RA患者。
主要发现
- 随访26534患者年,发生239例MACE和362例iCVE。
- DAS28-CRP与bDMARD使用对MACE交互作用显著(p=0.017);bDMARD未使用者(n=3855)DAS28-CRP每增1单位MACE风险HR 1.21(95%CI 1.07-1.37),使用者(n=515)HR 0.69(95%CI 0.40-1.20)。
- CRP(每对数单位增加)与bDMARD使用对MACE交互作用显著(p=0.011);未使用者CRP与MACE风险相关HR 1.16(95%CI 1.04-1.30),使用者HR 0.65(95%CI 0.36-1.17)。
- bDMARD使用与DAS28-CRP(p=0.167)或CRP(p=0.237)对iCVE风险无显著交互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Chronic inflammation promotes cardiovascular risk in rheumatoid arthritis (RA). Biological disease-modifying antirheumatic drugs (bDMARDs) improve disease activity and cardiovascular disease outcomes. We explored whether bDMARDs influence the impact of disease activity and inflammatory markers on long-term cardiovascular risk in RA. METHODS: We studied 4370 participants without cardiovascular disease in a 10-country observational cohort of patients with RA. Endpoints were (1) major adverse cardiovascular events (MACE) encompassing myocardial infarction, stroke and cardiovascular death; and (2) any ischaemic cardiovascular events (iCVE) including MACE plus revascularisation, angina, transient ischaemic attack and peripheral arterial disease. RESULTS: Over 26 534 patient-years, 239 MACE and 362 iCVE occurred. The interaction between 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP) and bDMARD use was significant for MACE (p=0.017), suggesting the effect of DAS28-CRP on MACE risk differed among bDMARD users (n=515) and non-users (n=3855). DAS28-CRP (per unit increase) is associated with MACE risk in bDMARD non-users (HR 1.21 (95% CI 1.07 to 1.37)) but not users (HR 0.69 (95% CI 0.40 to 1.20)). The interaction between CRP (per log unit increase) and bDMARD use was also significant for MACE (p=0.011). CRP associated with MACE risk in bDMARD non-users (HR 1.16 (95% CI 1.04 to 1.30)), but not users (HR 0.65 (95% CI 0.36 to 1.17)). No interaction was observed between bDMARD use and DAS28-CRP (p=0.167) or CRP (p=0.237) for iCVE risk. CONCLUSIONS: RA activity and inflammatory markers associated with risk of MACE in bDMARD non-users but not users suggesting the possibility of biological-specific benefits locally on arterial wall independently of effects on systemic inflammation.
引用
- Karpouzas GA, Ormseth SR, van Riel PLCM, et al. Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis. RMD Open. 2024. PMID: 39043615. doi:10.1136/rmdopen-2024-004546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。